• PDF / 169,147 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 35 Downloads / 156 Views

DOWNLOAD

REPORT

---

1 S

Palmar-plantar erythrodysesthesia syndrome: case report In a retrospective study (between 2017 and 2019) involving 11 patients, a 73-year-old man was described, who developed grade III palmar-plantar erythrodysesthesia syndrome during treatment with tegafur/uracil for thymic carcinoma. The man had a history of thymic carcinoma. His previous chemotherapy included fluorouracil/cisplatin (5-FU/cisplatin) with concurrent chemoradiotherapy. During the study period, he received treatment with oral tegafur/uracil 200mg twice daily, 3 weeks on, and 1 week off. Subsequently, he developed grade III palmar-plantar erythrodysesthesia syndrome [duration of treatment to reaction onset not stated]. Therefore, his treatment with tegafur/uracil was interrupted. Eventually, the palmar-plantar erythrodysesthesia resolved. Huang S-Y, et al. Efficacy and safety of uracil-tegafur in patients with recurrent or metastatic thymic carcinoma. Journal of Cancer Research and Practice 7: 111-115, No. 3, 803517280 Sep 2020. Available from: URL: http://doi.org/10.4103/JCRP.JCRP_11_20

0114-9954/20/1832-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 28 Nov 2020 No. 1832